Search results
Results From The WOW.Com Content Network
Shares of the California-based company fell 16% in extended trading. The decision comes after two failed attempts to secure regulatory approval for the expanded use of pimavanserin in the ...
Total equity. US$699.14 million (2019) Number of employees. 570 (June 30, 2020) Website. acadia .com. Footnotes / references. [1] Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California.
Acadia has an antipsychotic drug sold under the brand name Nuplazid approved for patients with a type of Parkinson's disease. The company's shares clawed back some lost ground and were last down 2.1%.
Talk. : Acadia Pharmaceuticals. This is the talk page for discussing improvements to the Acadia Pharmaceuticals article. This is not a forum for general discussion of the article's subject. Click here to start a new topic. Assume good faith. Be polite and avoid personal attacks. Be welcoming to newcomers.
Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase ...
Acadia (ACAD) delivered earnings and revenue surprises of 38.64% and 4.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
ACADIA Pharmaceuticals was on fire yesterday, up 24% after presenting data for its antipsychotic pimavanserin at the American Academy of Neurology annual meeting. The data looked good.
In this article you are going to find out whether hedge funds think ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a good investment right now. We like to check what the smart money thinks first ...